Lantheus Holdings reported a 1.5% increase in Q3 2026 revenue to $389.9 million, driven by strong sales in neurology and cardiology products despite a slight dip in oncology sales. The company received FDA approvals for TAUKLARIFY, a tau PET imaging agent for Alzheimer's assessment, and BRAVNETSA, a radiopharmaceutical for neuroendocrine tumors. Lantheus also announced a definitive $8 billion merger agreement with Curium, aiming to create a global radiopharmaceutical leader. The merger is expected to expand their diagnostic and therapeutic capabilities across more than 70 countries.
Lantheus Holdings Q3 2026 results provide context for readers. Of 150 priced health-sector US stocks on Pluang, 94 rose and 48 fell as of Nov 05, 2026 19:01 WIB. Notable movers include ALMS at USD 6.20 (-5.34%), OSCR at USD 36.95 (+5.00%, 41% Sell / 59% Buy), and ADPT at USD 27.99 (+4.79%, 0% Sell / 100% Buy).
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
